PMOS

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Retrieved on: 
Tuesday, February 20, 2024

In addition to receiving Rare Pediatric Disease Designation, AOC 1044 has been granted Orphan Designation by the FDA and the European Medicines Agency (EMA), and Fast Track Designation by the FDA.

Key Points: 
  • In addition to receiving Rare Pediatric Disease Designation, AOC 1044 has been granted Orphan Designation by the FDA and the European Medicines Agency (EMA), and Fast Track Designation by the FDA.
  • "We are pleased that the FDA has granted Rare Pediatric Disease designation to AOC 1044, adding to the Orphan Drug and Fast Track designations already granted.
  • Avidity plans to provide a first look at AOC 1044 data in people living with DMD44 in 2H 2024.
  • The EXPLORE44 trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial to evaluate AOC 1044 in healthy volunteers and participants with DMD mutations amenable to exon 44 skipping (DMD44).

LitheSpeed LLC Advances Enterprise Agility with the Announcement of Comprehensive Agile VMO® Services

Retrieved on: 
Thursday, January 18, 2024

LitheSpeed LLC, the original creator of, and the seminal thought leader behind the Agile Value Management Office (Agile VMO®) announces comprehensive Agile VMO® Services, marking a significant advancement in the field of enterprise agility.

Key Points: 
  • LitheSpeed LLC, the original creator of, and the seminal thought leader behind the Agile Value Management Office (Agile VMO®) announces comprehensive Agile VMO® Services, marking a significant advancement in the field of enterprise agility.
  • Consulting Services: These services aim to help organizations build a robust foundation in Strategic Agility.
  • The key focus is on transitioning from traditional Project Management Offices (PMOs) or Agile Centers of Excellence (COEs) to Agile Value Management Offices (VMOs).
  • Agile VMOs are designed to align enterprise work with business outcomes while integrating risk management and disciplined governance.

Project Management in the AI Era: A Roadmap for Enhanced Efficiency and Strategic Success Published by Info-Tech Research Group

Retrieved on: 
Friday, January 26, 2024

The firm's blueprint provides IT and PPM leaders with a roadmap for efficient resource allocation, real-time decision-making, and strategic business objectives project alignment, leveraging AI to transform traditional project management practices.

Key Points: 
  • The firm's blueprint provides IT and PPM leaders with a roadmap for efficient resource allocation, real-time decision-making, and strategic business objectives project alignment, leveraging AI to transform traditional project management practices.
  • Info-Tech Research Group, a global leader in IT research and advisory, has released its latest blueprint, Exponential IT for Project and Portfolio Management .
  • Info-Tech's blueprint highlights how PPM activities, such as portfolio management, resource management, budgeting, and performance monitoring, will be significantly enhanced through AI automation.
  • This initiative will enable project management teams to shift their focus from administrative duties to strategic problem-solving and forward-looking tasks.

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue

Retrieved on: 
Monday, January 8, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2023 net product revenue and cash on hand as of December 31, 2023, as part of its presentation today at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2023 net product revenue and cash on hand as of December 31, 2023, as part of its presentation today at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.
    Fourth quarter and full-year 2023 net product revenue for ELEVIDYS are expected to be approximately $131.3 million and $200.4 million, respectively.
  • Sarepta’s expected net product revenue does not include collaboration revenue.
  • Fourth quarter and full-year 2023 net product revenue for Sarepta’s RNA-based PMOs are expected to be approximately $234.3 million and $945.0 million, respectively.
  • Sarepta will report its final and complete fourth quarter and full-year 2023 financial results in late February 2024.

Omni Design Technologies Announces Expanded Silicon IP Solutions on Multiple TSMC Processes

Retrieved on: 
Wednesday, November 29, 2023

Omni Design Technologies , a leading provider of high-performance, low-power mixed-signal Intellectual Property (IP), today announced expanded silicon IP solutions on TSMC’s industry-leading 16nm, 12nm, and 7nm processes as part of Omni Design’s Swift™ high speed data converters offering ultrawide bandwidths.

Key Points: 
  • Omni Design Technologies , a leading provider of high-performance, low-power mixed-signal Intellectual Property (IP), today announced expanded silicon IP solutions on TSMC’s industry-leading 16nm, 12nm, and 7nm processes as part of Omni Design’s Swift™ high speed data converters offering ultrawide bandwidths.
  • These products enable applications such as wireless and wireline communications, automotive ADAS, LiDAR, Radar, and satellite communications.
  • The new product offerings include:
    Swift™ ADCs: All offer excellent in-band spurious-free dynamic range and noise spectral density performance with low power.
  • Process, voltage, and temperature monitors: Provides process monitoring of PMOS, NMOS as well as I/O devices, temperature monitoring with multiple differential or single ended voltage inputs.

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, November 1, 2023

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023.
  • Total net product revenue stands at $309.3 million, growing 49 percent over the same quarter last year.
  • These non-GAAP measures are not intended to be considered in isolation or to replace the presentation of the Company’s financial results in accordance with GAAP.
  • All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

Project Management Institute Celebrates Excellence in the Project Management Industry with Winners of 2023 PMI® Awards

Retrieved on: 
Friday, October 27, 2023

Project Management Institute (PMI), the world's leading organization for the project management profession, announced the winners of the 2023 PMI® Awards during a reception at PMI® Global Summit , its annual signature event.

Key Points: 
  • Project Management Institute (PMI), the world's leading organization for the project management profession, announced the winners of the 2023 PMI® Awards during a reception at PMI® Global Summit , its annual signature event.
  • The PMI® Awards highlight project professionals, PMI chapters, and published works that advance the project management profession.
  • PMI® Large and Mega Project Award and PMI® Small and Mid-Size Project Award – These awards recognize excellence in project management practices including superior organizational results, innovation, and positive impacts on society.
  • PMI® Linn Stuckenbruck Teaching Excellence Award – The PMI Linn Stuckenbruck Teaching Excellence Award honors faculty members for excellence in teaching project management curricula in higher education.

Project Management Institute to Acquire PMO Global Alliance to Build and Strengthen PMO Community Around the World

Retrieved on: 
Thursday, October 26, 2023

Project Management Institute (PMI), the world's leading organization for the project management profession, has signed an agreement to acquire PMO Global Alliance (PMOGA), the largest global community of PMOs and PMO professionals.

Key Points: 
  • Project Management Institute (PMI), the world's leading organization for the project management profession, has signed an agreement to acquire PMO Global Alliance (PMOGA), the largest global community of PMOs and PMO professionals.
  • Founded in 2017, PMOGA is a global community with more than 17,000 members in more than 125 countries.
  • PMOGA developed two professional certifications – the PMO Certified Practitioner (PMO-CP) and the PMO Certified Consultant (PMO-CC) certifications.
  • The organization also hosts its own award program, the PMO Global Awards, to celebrate the most accomplished PMOs and PMO professionals.

United States Continuing Medical Education Market Outlook Report 2023: A $4.23 Billion Market by 2028 - ChatGPT & Gamification at the Forefront of Innovations and Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 23, 2023

Continuing Medical Education Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Continuing Medical Education Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. continuing medical education market is expected to reach a value of $4.23 billion by 2028 from $2.91 billion in 2022, growing at a CAGR of 6.43%
    The U.S. continuing medical education market is highly competitive with the presence of types of CME provider vendors.
  • In continuing medical education (CME), gamification is one trending learning strategy that fulfills the gaps of remote continuing medical education.
  • Further, gamification is growth-delivering potential factors across the U.S. continuing medical education market and offers lucrative growth opportunities.

United States Continuing Medical Education Market Outlook Report 2023-2028: U.S. Healthcare's Crucial Need for Quality and Affordability Drives the Continual Growth of CME Providers

Retrieved on: 
Friday, August 18, 2023

Continuing Medical Education Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Continuing Medical Education Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In continuing medical education (CME), gamification is one trending learning strategy that fulfills the gaps of remote continuing medical education.
  • Further, gamification is growth-delivering potential factors across the U.S. continuing medical education market and offers lucrative growth opportunities.
  • Across the U.S., CME credit is mandatory for healthcare professionals, which is the major factor accelerating the U.S. continuing medical education market.